Infusion of allogeneic anti-CD19 CAR T-cells is a promising approach after alloHSCT

Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.

Year of Production:
Running Time:
Color/Sound:

2015
14:22
Color/Sound

Comments are closed.